title: Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
abstract: Arsenic trioxide has been used successfully for the treatment of refractory acute promyelocytic leukemia and has shown promise in the treatment of myelodysplastic syndrome (MDS), although it is not a labeled indication. Retinoic acid syndrome is manifested by fever, dyspnea, peripheral edema, pulmonary infiltrates, and pleural and/or pericardial effusions and is typically seen in conjunction with all- trans retinoic acid therapy of acute promyelocytic leukemia. We report a case of acute lung injury and a retinoic acid syndrome-like illness in a patient who received arsenic for MDS. To our knowledge, this is the first such report, and clinicians should be aware of this potentially life-threatening complication of arsenic trioxide treatment in patients with MDS.
authors: Division of Pulmonary and Critical Care Medicine, Department of Medicine, Rush Medical College and Rush University Medical Center, Chicago, IL 60612, USA. hhassaba@rush.edu
authors: Hesham A
authors: HA
authors: Hassaballa
authors: Omar B
authors: OB
authors: Lateef
authors: Michael R
authors: MR
authors: Silver
authors: Robert A
authors: RA
authors: Balk
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use; D012128:Respiratory Distress Syndrome / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide